Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$7.02 -0.82%

-$0.17 today

Market cap
$290.28M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.90M

Average 0.38M

EVMN Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Evommune, Inc.NYSE: EVMN

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Context

  • Gross margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
100.0%+18.4 pp YoY
LTMMar 2026
92.8%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year+18.4 pp——
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
100.0%
Year-over-year change
+18.4pp

Gross Margin vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 gross margin of 92.8% is the 3rd highest of the 8 companies compared; the peer median is 76.5%.
EVMN Competitors Peer median
Gross Margin for EVMN and competitors
Company Period LTM level YoY 3-year change
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202698.6% +10.9 pp+24.5 pp
KPTIKaryopharm Therapeutics Inc.LTM Mar 202696.0% -0.1 pp-0.8 pp
EVMNEvommune, Inc.LTM Mar 202692.8% ——
CDXSCodexis, Inc.LTM Mar 202683.9% +12.4 pp+14.2 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202676.5% -16.8 pp+13.5 pp
ZYMEZymeworks Inc.LTM Sep 202668.6% -31.4 pp+0.0 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
FTREFortrea Holdings Inc.LTM Jun 202617.1% -1.9 pp-9.9 pp
CLYMClimb Bio, Inc.FY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
Peer median (excluding EVMN) 76.5%-1.9 pp+0.0 pp

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5M7M13M
Cost of Revenue1M1.29M0
Gross Profit4M5.71M13M
Gross Margin80.0%81.6%100.0%
Research & Development32M64.24M74.04M
Selling, General & Admin9.85M11.48M20.03M
Operating Expenses41.85M75.73M94.07M
Depreciation & Amortization1M1.29M1.39M
EBITDA(33M)(65.49M)(67.48M)
EBITDA Margin-659.9%-935.5%-519.1%
Operating Income(37.85M)(70.01M)(81.07M)
Operating Margin-757.0%-1000.2%-623.6%
Interest Income3.86M3.24M3.32M
Interest Expense58K34K0
Other Income / Expenses3.8M3.2M12.2M
Income Before Tax(34.05M)(66.81M)(68.87M)
Pre-Tax Margin-681.1%-954.4%-529.8%
Income Tax Expense000
Net Income(34.05M)(66.81M)(68.87M)
Net Margin-681.1%-954.4%-529.8%
EPS (Basic)(1.13)(2.27)(2.18)
EPS (Diluted)(1.13)(2.27)(2.18)
Weighted Avg Shares30.08M30.08M31.52M
Weighted Avg Shares (Diluted)30.08M30.08M31.52M

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$7.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.